Sun SS, Guo XD, Li WD, Chen JL. Lenvatinib combined with sintilimab plus transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma. World J Clin Cases 2024; 12(2): 285-292 [PMID: 38313649 DOI: 10.12998/wjcc.v12.i2.285]
Corresponding Author of This Article
Jing-Long Chen, MS, Associate Professor, Department of Oncology, Capital Medical University Affiliated Beijing Ditan Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. hhh540027@126.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Sha-Sha Sun, Xiao-Di Guo, Wen-Dong Li, Jing-Long Chen, Department of Oncology, Capital Medical University Affiliated Beijing Ditan Hospital, Beijing 100015, China
Author contributions: Sun SS and Chen JL designed the experiment; Sun SS and Guo XD collected the data; Guo XD and Li WD analysed data; Sun SS and Chen JL wrote and revised the manuscript.
Supported byCapital Health Development and Scientific Research Special Project, No. 2022-2-2175.
Institutional review board statement: The study was reviewed and approved by Beijing Ditan Hospital Affiliated to Capital Medical University Institutional Review Board (Approval No. 014-01).
Informed consent statement: Written informed consent was obtained from every patient prior to treatment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing-Long Chen, MS, Associate Professor, Department of Oncology, Capital Medical University Affiliated Beijing Ditan Hospital, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. hhh540027@126.com
Received: November 20, 2023 Peer-review started: November 20, 2023 First decision: December 5, 2023 Revised: December 13, 2023 Accepted: December 27, 2023 Article in press: December 27, 2023 Published online: January 16, 2024
ARTICLE HIGHLIGHTS
Research background
Hepatocellular carcinoma (HCC) is a serious global health problem because current treatments have limited efficacy for treating HCC patients, especially those with advanced-stage HCC. Recently, combination therapy has shown better trends in tumour response and survival than monotherapy. However, research on triple therapy [lenvatinib + sintilimab + transarterial chemoembolization (TACE)] as a first-line treatment for advanced HCC is limited.
Research motivation
Although current studies of advanced HCC indicate promising efficiency of tyrosine kinase inhibitors or death protein-1 inhibitors, the objective response rate remains unsatisfactory.
Research objectives
The study evaluated the safety and clinical efficacy of triple therapy in HCC patients with Barcelona Clinic Liver Cancer stage C.
Research methods
The primary outcome of the study was overall survival. The secondary outcomes were the objective response rate (ORR), disease control rate (DCR), and incidence of adverse events.
Research results
The ORR and DCR were 45% and 90%, respectively. Common complications were observed in 76% of the patients (grade 3, 15%; grade 4, 2.5%).
Research conclusions
Combination therapy comprising lenvatinib, sintilimab and TACE achieved promising outcomes in advanced HCC patients and had manageable effects.
